 CytoDyn Inc OTCQB:CYDY announced that it has submitted a dose justification report on its Vyrologix leronlimab-PRO 140 drug to the US Food and Drug Administration FDA, which will be followed by an official submission for an IND investigational new drug. The late-stage biotechnology company is developing leronlimab to battle multiple diseases, including coronavirus COVID-19. 